ReviewClinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology2025
Hereditary Angioedema (HAE) in China: Advancing Awareness, Access, Advocacy and Alliances From the Greater Bay Area to the Global HAE Community.
Review in Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Lanadelumab safety, efficacy, and pharmacokinetics in patients aged ≥12 with hereditary angioedema in China: an open-label, multicenter study.Frontiers in immunology · 2026Trial
- Limited access to on-demand treatment in hereditary angioedema is linked to delayed treatment and impaired patient-reported outcomes: A multinational real-world study.The journal of allergy and clinical immunology. Global · 2026Article
- Global research trends in hereditary angioedema, 1972-2023: Bibliometric analysis of productivity, collaboration, and thematic evolution.The World Allergy Organization journal · 2026Article
- Developing a patient journey map to improve care and experience in Chinese patients with hereditary angioedema.The World Allergy Organization journal · 2026Article
- A single-centre retrospective study on the clinical characteristics of patients with hereditary angioedema and the therapeutic effect of lanadelumab.Orphanet journal of rare diseases · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The article offers an overview of the progress in managing Hereditary Angioedema (HAE) in China, with a specific focus on the Greater Bay Area (GBA). Through the '4As' framework-Awareness, Access, Advocacy and Alliance-the article explores the challenges and advancements in HAE care. In terms of collaborative initiatives such as the HAE-ASIA (Angioedema Screening In Asia) collaboration and the GBA HAE Alliance "Hub-and-Spoke model" aim to bridge the gap between East and West, providing optimal patient care and advancing HAE management. By bridging the gap between East and West, the GBA aims to deliver optimal patient care and advance HAE management. Moving forward, it will be essential to persist in nurturing national and international collaborations, not only within China but also extending beyond its borders. These partnerships encourage the exchange of knowledge, research, and best practices, all of which are critical in propelling forward the care of HAE. By uniting as a worldwide community, we can significantly advance efforts to improve the quality of life for those affected by HAE across the globe.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.